We recently compiled a list of the Why These 24 Stocks Are Skyrocketing. In this article, we are going to take a look at where Chimerix, Inc. (NASDAQ:CMRX) stands against the other stocks. One of the ...

Chimerix meets financial expectations during Q2, 2023 earnings call. Investment thesis for Chimerix focuses on its ONC201 study expected to read out in 2026. Company has high risk of loss despite ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Chimerix ( (CMRX)) has shared an ...

-Transaction represents total cash consideration of approximately $935 million, or $8.55 per share- DUBLIN and DURHAM, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ...

DURHAM, N.C., June 24, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients ...

On Monday, Chimerix (NASDAQ:CMRX) announced that, following extensive dialogue with the FDA, the company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for ...

Jazz Pharmaceuticals has agreed to acquire Chimerix for approximately $935 million, the companies said Wednesday, in a deal designed to bolster the buyer’s rare oncology portfolio with a treatment ...

On Tuesday, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) agreed to acquire Chimerix Inc (NASDAQ:CMRX) for $8.55 per share in cash, representing a total consideration of approximately $935 million. Both ...